LDLR AND KLF2 ARE CRITICAL MEDIATORS IN STATIN-INDUCED CELL DEATH IN AML

EHA Library, Yuta Fukui, 4207471

COMPUTATIONAL ASSESSMENT OF CD34+CD38- ACUTE MYELOID LEUKEMIA STEM CELL FREQUENCY AT DIAGNOSIS

EHA Library, Felix Zwolle, 4207472

INDOLE-3-ACETIC ACID REVERSES VENETOCLAX RESISTANCE IN ACUTE MYELOID LEUKEMIA VIA THE JAK2/STAT3 SIGNALING PATHWAY

EHA Library, Haiping Liang, 4207474

ESTABLISHMENT OF TRANSLATIONAL 3D AML BONE MARROW-ON-CHIP MODELS TO STUDY BONE MARROW NICHE INTERACTION AND DRUG SENSITIVITY

EHA Library, Nurbanu Erölmez, 4207475

NOVEL RANDOM SURVIVAL FOREST MODEL FOR PRECISION RISK STRATIFICATION IN NPM1-MUTATED ACUTE MYELOID LEUKEMIA

EHA Library, Yiyi Yao, 4207479

HEAD-TO-HEAD COMPARISON OF SIX CONTEMPORARY PROGNOSTIC MODELS IN NON-INTENSIVE FRONTLINE ACUTE MYELOID LEUKEMIA TREATED IN THE VENETOCLAX ERA: A MULTICENTER CETLAM COOPERATIVE GROUP STUDY

EHA Library, Tomas Rivero Equiza, 4207480

CD7 CAR T-CELL THERAPY IN RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

EHA Library, Zhao defeng, 4207481

PHASE 1/2 STUDY OF THE ALL-ORAL COMBINATION OF REVUMENIB (SNDX-5613) WITH DECITABINE/CEDAZURIDINE (ASTX727) AND VENETOCLAX (SAVE) IN RELAPSED/REFRACTORY AML

EHA Library, Branko Cuglievan, 4207483

GENOMIC SIGNATURE AND CLINICAL FEATURES OF DHX15 MUTATED RUNX1::RUNX1T1 AML.

EHA Library, Eleonora Boscaro, 4207485

POOR RESPONSE OF VENETOCLAX AND AZACITIDINE IN MONOCYTIC ACUTE MYELOID LEUKEMIA IS ASSOCIATED WITH GENETIC PATTERNS AND IS IMPROVED BY ADDITION OF HOMOHARRINGTONINE, A MULTI-CENTER COHORT STUDY

EHA Library, Guopan Yu, 4207487

SAFETY AND EFFICACY OF IADADEMSTAT PLUS GILTERITINIB IN THE FRIDA EXPANSION COHORT OF FLT3‑MUTATED RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA

EHA Library, Amir Fathi, 4207489

PROSPECTIVE VALIDATION OF MAC-SCORING IN AML ALLOWS SAME DAY PREDICTION OF HMA/VENETOCLAX RESPONSE

EHA Library, Simon Renders, 4207490

MITOXANTRONE LIPOSOME, SUBCUTANEOUS CYTARABINE AND G-CSF COMBINED WITH VENETOCLAX AS FIRST-LINE TREATMENT IN SECONDARY AML PATIENTS: A MULTICENTER, PROSPECTIVE CLINICAL TRIAL WITH CONCURRENT CONTROL

EHA Library, Sujiang Zhang, 4207492

VENETOCLAX PLUS CLADRIBINE AND 5-AZACITIDINE (VCAZA) AS INDUCTION THERAPY IN NEWLY DIAGNOSED OLDER, UNFIT OR YOUNG HIGH-RISK ACUTE MYELOID LEUKEMIA: A PROSPECTIVE, SINGLE-ARM, PHASE II STUDY

EHA Library, Cong Wang, 4207493

QUIZARTINIB WITH REINDUCTION CHEMOTHERAPY AND AS SINGLE-AGENT MAINTENANCE IN CHILDREN AND ADOLESCENTS WITH RELAPSED/REFRACTORY FLT3-ITD+ AML: A PHASE 1/2 MULTICENTER STUDY

EHA Library, C. Michel Zwaan, 4207494

LONG-TERM FOLLOW-UP OF PEDIATRIC/YOUNG ADULT PATIENTS WITH RELAPSED/REFRACTORY KMT2AR ACUTE LEUKEMIA TREATED WITH REVUMENIB IN AUGMENT-101

EHA Library, Branko Cuglievan, 4207496

HYPOMETHYLATING AGENTS PLUS VENETOCLAX IN YOUNGER AML: META-ANALYSIS OF A SHIFTING TREATMENT PARADIGM

EHA Library, Matteo Molica, 4207498

OUTCOMES AND RISK STRATIFICATION WITH HIGH-DOSE CYTARABINE, MITOXANTRONE, AND VENETOCLAX IN RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

EHA Library, Andrew Berdel, 4207499

INDIRECT COMPARISON OF IVOSIDENIB + VENETOCLAX + AZACITIDINE VERSUS DOUBLET REGIMENS IN INTENSIVE CHEMOTHERAPY-INELIGIBLE IDH1-MUTATED ACUTE MYELOID LEUKEMIA

EHA Library, Jennifer Marvin-Peek, 4207501

EFFICACY OF REVUMENIB IN ACUTE MYELOID LEUKEMIA HARBORING NPM1-MUTATED CO-MUTATIONS: POST HOC ANALYSIS OF AUGMENT-101

EHA Library, James S. Blachly, 4207502

OPTIMIZED CD33(FL33) CAR-T CELLS IN RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA: A PHASE 1/2CLINICAL TRIAL

EHA Library, Jing Pan, 4207503

MEASURABLE RESIDUAL DISEASE MONITORING IN PATIENTS WITH ACUTE MYELOID LEUKEMIA PRE- AND POST-ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION TO ASSESS RISK OF RELAPSE USING 16 KEY AML-ASSOCIATED GENES

EHA Library, Sean Glenn, 4207504

ISOCITRATE DEHYDROGENASE-1 TESTING AND FIRST-LINE TREATMENT IN PATIENTS WITH EUROPEAN LEUKAEMIA NETWORK-DEFINED ACUTE MYELOID LEUKAEMIA INELIGIBLE FOR INTENSIVE THERAPY: A MULTI-COUNTRY SURVEY

EHA Library, Alessandro Isidori, 4207505

IMPACT OF PRIOR INDUCTION CYCLE NUMBER ON OUTCOMES WITH GILTERITINIB IN RELAPSED/REFRACTORY FLT3-MUTATED AML: A POOLED POST-HOC ANALYSIS OF ADMIRAL AND COMMODORE STUDIES

EHA Library, Mark Levis, 4207509

GEMTUZUMAB OZOGAMICIN (GO) IN COMBINATION WITH CYTARABINE (ARA-C) IN RELAPSED ACUTE MYELOID LEUKEMIA (R-AML)

EHA Library, Giulia Arrigo, 4207510

COMBINED FADS1 AND FADS2 EXPRESSION IS ASSOCIATED WITH PROGNOSIS AND RISK CLASSIFICATION IN PEDIATRIC ACUTE MYELOID LEUKEMIA

EHA Library, Yijun Wu, 4207512

POPULATION-BASED STUDY OF ACUTE PROMYELOCYTIC LEUKEMIA IN GERMANY: INCIDENCE AND SURVIVAL OUTCOMES

EHA Library, David Baden, 4207513

ZEFAMENIB COMBINED WITH CHEMOTHERAPY OR TARGETED AGENTS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA: PRELIMINARY RESULT OF AN OPEN-LABEL, PHASE I/II STUDY

EHA Library, Haiping Dai, 4207514

DNMT3A MUTANTS COMBINED WITH POST-CONSOLIDATION MRD STATUS IMPROVES RISK STRATIFICATION IN ACUTE MYELOID LEUKEMIA WITHOUT RECEIVING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

EHA Library, Jiayan Gu, 4207516

UPDATED FINDINGS FROM THE PHASE 2 RIVER-81 STUDY OF ROMACICLIB (RVU120) COMBINED WITH VENETOCLAX IN ACUTE MYELOID LEUKEMIA AFTER FIRST-LINE VENETOCLAX AND HYPOMETHYLATING AGENT FAILURE

EHA Library, Pau Montesinos, 4207517

UPDATED RESULT OF SELINEXOR-BASED NON-INTENSIVE CHEMOTHERAPY REGIMENS ADJUSTED ACCORDING TO EARLY RESPONSES ACHIEVE HIGH EARLY REMISSION IN NEWLY DIAGNOSED AML OR MDS

EHA Library, Donghua Zhang, 4207518

AUTOMATIC AND EXPLAINABLE ANALYSIS OF BONE MARROW SMEARS USING MACHINE LEARNING METHODS : AN INNOVATIVE MODEL FOR THE DIAGNOSIS OF ACUTE MYELOID LEUKEMIA

EHA Library, Jules Morata, 4207521

FEASIBILITY AND CLINICAL IMPACT OF CYTARABINE CONSOLIDATION FOR AML IN A FULL OUTPATIENT SETTING

EHA Library, Marina Vallvé i Oliva, 4207522

DNMT3A R882 HOTSPOT MUTATION DEFINES A HIGH-RISK SUBGROUP IN TREATMENT-NAÏVE AML IRRESPECTIVE OF CO-MUTATION STATUS

EHA Library, Zheng Ge, 4207523

REAL-WORLD MANAGEMENT PRACTICES WITH VENETOCLAX-BASED THERAPY FOR AML - RESULTS FROM THE PROSPECTIVE REVIVE STUDY

EHA Library, Yakir Moshe, 4207524

EXPOSURE-RESPONSE ANALYSIS OF ZIFTOMENIB COMBINED WITH VENETOCLAX/AZACITIDINE OR CYTARABINE/DAUNORUBICIN IN NEWLY DIAGNOSED AND RELAPSED/REFRACTORY NPM1-M OR KMT2A-R ACUTE MYELOID LEUKEMIA

EHA Library, Amitava Mitra, 4207525

DETERMINANTS OF SURVIVAL IN 356 PATIENTS FAILING FRONTLINE VENETOCLAX–HMA FOR NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA

EHA Library, Naseema Gangat, 4207527

LOW-DOSE INDUCTION CHEMOTHERAPY IS ASSOCIATED WITH VERY LOW EARLY MORTALITY IN PEDIATRIC ACUTE MEGAKARYOBLASTIC LEUKEMIA: A PROSPECTIVE MULTICENTER STUDY

EHA Library, Shengqin Cheng, 4207529

REVUMENIB IN THE REAL WORLD: INTERIM FINDINGS FROM THE ROAR STUDY IN RELAPSED/REFRACTORY ACUTE LEUKEMIA

EHA Library, Shai Shimony, 4207530

PROOF-OF-CONCEPT: DEEP LEARNING-BASED PREDICTION OF MEASURABLE RESIDUAL DISEASE IN ACUTE MYELOID LEUKEMIA WITHOUT REFERENCE VALUES

EHA Library, Maximilian Roehnert, 4207533

FLAG-MITOXANTRONE WITH 7 DAYS VENETOCLAX IS A HIGHLY EFFICIENT REGIMEN IN NEWLY DIAGNOSED ACUTE MYELOBLASTIC LEUKEMIA AND AN EFFECTIVE BRIDGE TO ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

EHA Library, Ahmad Ibrahim, 4207534

CLADRIBINE COMBINED WITH LOW-DOSE CYTARABINE AND G-CSF IN UNFIT REFRACTORY/RELAPSED ACUTE MYELOID LEUKEMIA

EHA Library, Qiaoyi Zhou, 4207537

A PHASE I/II STUDY OF GILTERITINIB AND MOMELOTINIB IN ADULTS WITH RELAPSED OR REFRACTORY FLT3-MUTATED ACUTE MYELOID LEUKEMIA

EHA Library, Nicholas Short, 4207538

IMPACT OF TIME TO TREATMENT ON OUTCOMES IN HYPERPROLIFERATIVE ACUTE MYELOID LEUKEMIA

EHA Library, Benjamin Mccormick, 4207539

EARLY RESULTS OF THE ONGOING PHASE II MAVEN STUDY: VENETOCLAX-AZACITIDINE-LIPOSOMAL MITOXANTRONE (VAM) IN MYELOID SARCOMA AND SECONDARY ACUTE MYELOID LEUKEMIA

EHA Library, Xinjie Chen, 4207541

ABSOLUTE LYMPHOCYTE COUNT AFTER INDUCTION CHEMOTHERAPY IS A PREDICTIVE BIOMARKER IN ACUTE MYELOID LEUKEMIA PATIENTS AND RELATES WITH POST-THERAPY CHANGES IN IMMUNE TRANSCRIPTOMIC BONE MARROW PROFILE.

EHA Library, Federico Zingarelli, 4207542

VENETOCLAX-AZACITIDINE-CHIDAMIDE PLUS CAG AS INDUCTION CHEMOTHERAPY FOR MYELODYSPLASIA-RELATED ACUTE MYELOID LEUKEMIA

EHA Library, Qingyang Liu, 4207544

SHORTER TREATMENT, FASTER DISCHARGE. THE IMPACT OF DAY 14 ASSESSMENT IN AML PATIENTS ON AZA-VEN: A SINGLE CENTER EXPERIENCE.

EHA Library, Felix Klingler, 4207547

REAL-WORLD EFFICACY AND SAFETY OF LISAFTOCLAX IN MYELOID NEOPLASMS: A MULTICENTER STUDY

EHA Library, Chen Cao, 4207550

PHARMACOKINETIC ASSESSMENT OF REVUMENIB IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE LEUKEMIAS HARBORING A KMT2A REARRANGEMENT OR NPM1 MUTATION: IMPACT OF FOOD AND CONCOMITANT MEDICATIONS

EHA Library, Ghayas Issa, 4207552

GILTERITINIB OR IVOSIDENIB IN COMBINATION WITH VENETOCLAX-BASED THERAPIES FOR FLT3- OR IDH1-MUTATED ACUTE MYELOID LEUKEMIA

EHA Library, Andrius Žučenka, 4207553

PTPN11 MUTATED ACUTE MYELOID LEUKEMIA: EVALUATION OF DOMAIN‑SPECIFIC MUTATIONS AND THEIR POTENTIAL IMPACT ON CO‑MUTATIONAL PROFILES AND CLINICAL OUTCOMES

EHA Library, Francesca Crupi, 4207556

STAT1 SIGNALING DRIVES MICROENVIRONMENT-MEDIATED VENETOCLAX RESISTANCE AND PROLIFERATION IN CLL

EHA Library, Miroslav Boudny, 4207557

CEBPB COUPLES B-CELL RECEPTOR SIGNALING TO CLL CELL PROLIFERATION AND SURVIVAL

EHA Library, Josef Vecera, 4207558

MYC OVEREXPRESSION DRIVES POOR PROGNOSIS AND DIFFERENTIAL SENSITIVITY TO TREATMENTS ACCORDING TO TP53 STATUS IN CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Alba Garrote-de-Barros, 4207559

BIOLOGICAL DETERMINANTS OF CLL MRD RESPONSE KINETICS WITH IBRUTINIB-VENETOCLAX IN THE FLAIR TRIAL

EHA Library, Andy Rawstron, 4207560

REVISITING COMPLEX KARYOTYPE IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS TREATED WITH CONTINUOUS BTK INHIBITION: A MULTICENTER ERIC STUDY

EHA Library, Anna Puiggros, 4207564

FERROPTOSIS AS A THERAPEUTIC TARGET IN CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Martin Boettcher, 4207566

SINGLE-CELL RNA AND BCR SEQUENCING REVEALS CLONAL EVOLUTION AND DISTINCT MICROENVIRONMENTAL HETEROGENEITY IN RICHTER TRANSFORMATION

EHA Library, jiaojiao zhang, 4207570

PTPN2 INHIBITION RESTORES T-CELL FUNCTION AND POTENTIATES T-CELL ENGAGER ACTIVITY IN CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Yair Herishanu, 4207572

DJ-1 REGULATES NECROPTOSIS THROUGH THE TNFAIP3–RIPK1 AXIS IN FLT3-ITD ACUTE MYELOID LEUKEMIA

EHA Library, shifeng lou, 4207469

LACTATE REGULATORY GENE LSP1 LEADING TO BCL-2 INHIBITOR RESISTANCE THROUGH DUAL EFFECTS BY PROMOTING AML CELL INVASION AND IMMUNE ESCAPE

EHA Library, Zhibo Guo, 4207470

DISCOVERY AND VALIDATION OF A ROBUST 11-GENE PROGNOSTIC SIGNATURE VIA INTEGRATIVE MULTI-OMICS PROFILING IN VD-CAG-TREATED NON-M3 AML

EHA Library, Jirui Tang, 4207473

CLINICAL FEATURES, TREATMENT PATTERNS AND OUTCOMES OF 4,351 ADULT PATIENTS WITH SECONDARY ACUTE LEUKEMIA: A PETHEMA STUDY

EHA Library, Pau Montesinos, 4207476

REVUMENIB + INTENSIVE CHEMOTHERAPY FOR NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA HARBORING GENETIC ALTERATIONS IN KMT2A, NPM1, OR NUP98: UPDATED PHASE 1 RESULTS FROM SNDX-5613-0708

EHA Library, Ibrahim Aldoss, 4207477

CHIDAMIDE PLUS VENETOCLAX AND AZACITIDINE (VAC) VERSUS VA REGIMEN IN NEWLY DIAGNOSED IMMUNOPHENOTYPICALLY MATURE MONOCYTIC AML: AN UPDATED ANALYSIS FROM A MULTICENTER RANDOMIZED STUDY

EHA Library, Kaiwen Tan, 4207478

A FIRST-IN-HUMAN STUDY OF THE ORAL CLK INHIBITOR BH-30236 IN ADULTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA OR HIGHER-RISK MYELODYSPLASTIC SYNDROME: MONOTHERAPY AND VENETOCLAX COMBINATION

EHA Library, Eytan Stein, 4207482

VENETOCLAX PLUS ‘2 + 5’ MODIFIED INTENSIVE CHEMOTHERAPY WITH DAUNORUBICIN AND CYTARABINE IN FIT ELDERLY PATIENTS WITH UNTREATED DE NOVO ACUTE MYELOID LEUKEMIA: A MULTICENTER PROSPECTIVE ANALYSIS

EHA Library, Jiajia Pan, 4207484

BIOLOGICAL FEATURES AND CLINICAL CHARACTERISTICS OF TP53-MUTATED AML: INSIGHTS FROM THE HARMONY PLATFORM

EHA Library, Rabea Mecklenbrauck, 4207486

THE EFFICACY OF PIVEKIMAB SUNIRINE (PVEK) IN PATIENTS (PTS) WITH BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM (BPDCN) WITH BASELINE SKIN INVOLVEMENT IN THE CADENZA STUDY

EHA Library, Naveen Pemmaraju, 4207488

LONG-TERM OUTCOMES WITH VENETOCLAX PLUS “7+3” (DAV) INDUCTION IN NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA

EHA Library, Huafeng Wang, 4207491

RESULTS FROM THE PHASE 1 MONOTHERAPY DOSE ESCALATION OF APL-4098, AN ORAL GCN2 INHIBITOR, IN RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (R/R AML) AND MYELODYSPLASTIC SYNDROMES (MDS)/AML PATIENTS

EHA Library, Nadine Clemo, 4207495

TRIPLET THERAPY WITH QUIZARTINIB, DECITABINE, AND VENETOCLAX IN NEWLY DIAGNOSED AND RELAPSED/REFRACTORY FLT3-ITD ACUTE MYELOID LEUKEMIA

EHA Library, Musa Yilmaz, 4207497

EFFICACY OF THE TRIPLET THERAPY WITH VENETOCLAX, AZACITIDINE AND GILTERITINIB FOR THE TREATMENT OF FLT3-ITD MUTATED R/R AML PATIENTS BRIDGING TO ALLOGENEIC STEM CELL TRANSPLANTATION

EHA Library, Chen Liang, 4207500

COMPREHENSIVE LANDSCAPE OF CODING AND NON-CODING DRIVER ALTERATIONS REVEALED BY DEEP WHOLE-GENOME SEQUENCING OF MYELOID NEOPLASMS

EHA Library, Koji Okazaki, 4207506

EXTENSIVE OVERLAP BETWEEN POST-CYTOTOXIC AND DE NOVO CBFB-MYH11-POSITIVE ACUTE MYELOID LEUKEMIA: A MULTICENTER STUDY IN CHINA

EHA Library, Linya Wang, 4207507

A PHASE II TRIAL OF TAGRAXOFUSP, HYPER-CVAD, AND VENETOCLAX FOR PATIENTS WITH NEWLY DIAGNOSED OR RELAPSED/REFRACTORY BPDCN

EHA Library, Hannah Goulart, 4207508

OUTCOMES AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IN ACUTE MYELOID LEUKEMIA TREATED WITH INTENSIVE CHEMOTHERAPY WITH VENETOCLAX

EHA Library, Leticia Campoverde, 4207511

FLAG-MITOXANTRONE-VENETOCLAX (7 DAYS) IS AN EFFICIENT SALVAGE THERAPY IN RELAPSED/REFRACTORY AML, WITH AN IMPACT OF NGS ON RESPONSE, AND AN EXCELLENT BRIDGE TO ALLOGENEIC STEM CELL TRANSPLANTATION

EHA Library, Ahmad Ibrahim, 4207515

EFFICACY AND SAFETY OF VENETOCLAX COMBINED WITH CAG REGIMEN AS INDUCTION THERAPY IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA: A MULTICENTER PHASE II STUDY

EHA Library, mei sun, 4207519

DECITABINE/CEDAZURIDINE WITH OR WITHOUT A SECOND TARGETED AGENT (VENETOCLAX, GILTERITINIB, ENASIDENIB, OR IVOSIDENIB) AS FULLY ORAL PERSONALIZED MAINTENANCE THERAPY IN ACUTE MYELOID LEUKEMIA

EHA Library, Alexandre Bazinet, 4207520

MACROPHAGE ACTIVATION-LIKE SYNDROME IN ACUTE MYELOID LEUKEMIA

EHA Library, Veronica Zimmer, 4207526

REAL-WORLD INSIGHTS INTO SALVAGE CHEMOTHERAPY FOR FIT FAVORABLE-RISK AML PATIENTS AT FIRST RELAPSE

EHA Library, Elisa Seubert, 4207528

A LARGE MULTICENTER REAL-WORLD STUDY DEMONSTRATES SUPERIOR OUTCOMES WITH VENETOCLAX-BASED REGIMENS IN ACUTE MYELOID LEUKEMIA HARBORING EZH2 MUTATIONS

EHA Library, Xiangli Chen, 4207532

VENETOCLAX PLUS AZACITIDINE FOR NEWLY DIAGNOSED LOW-RISK NPM1-MUTATED ACUTE MYELOID LEUKEMIA: A PROSPECTIVE STUDY

EHA Library, Xueqing Dou, 4207535

REAL-WORLD TREATMENT PATTERNS AND OUTCOMES OF PATIENTS WITH RELAPSED/REFRACTORY IDH1-MUTATED ACUTE MYELOID LEUKEMIA TREATED WITH IVOSIDENIB

EHA Library, Vanessa Kennedy, 4207536

HEALTHY HUMAN STUDY OF A NOVEL ORAL BCL-2 INHIBITOR LONITOCLAX (ZE50-0134) AND EARLY RESULTS OF A PHASE 1/B STUDY OF LONITOCLAX TOGETHER WITH AZACITIDINE IN RELAPSED AND REFRACTORY AML

EHA Library, John Byrd, 4207540

NO EVIDENCE OF QTC INTERVAL PROLONGATION WITH THE MENIN INHIBITOR BLEXIMENIB WHEN GIVEN AS MONOTHERAPY OR IN COMBINATION WITH AML-DIRECTED THERAPIES FOR KMT2A OR NPM1 ALTERED AML

EHA Library, Maher Abdul-Hay, 4207543

SAFETY RUN-IN RESULTS OF THE CHIP-AML22 PHASE II TRIAL EVALUATING QUIZARTINIB COMBINED WITH CHEMOTHERAPY IN PEDIATRIC PATIENTS WITH NEWLY DIAGNOSED FLT3-ITD–POSITIVE, NPM1–WILD-TYPE  AML

EHA Library, Gertjan Kaspers, 4207545

NEWER AML RISK SCORES IMPROVE RISK STRATIFICATION IN CPX-351 TREATED S-AML PATIENTS COMPARED TO ELN2022, BUT A TAILORED PROGNOSTIC MODEL IS STILL NEEDED

EHA Library, Carola Riva, 4207548

EFFICACY OF VENETOCLAX-BASED REGIMENS AS SALVAGE THERAPY, FOLLOWED BY ALLOGENEIC TRANSPLANTATION, IN RELAPSED/REFRACTORY AML PATIENTS.

EHA Library, Matteo Fanin, 4207549

CLINICAL OUTCOMES AFTER FAILURE OF AZACITIDINE PLUS VENETOCLAX FOR FRONTLINE TREATMENT OF ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA

EHA Library, Zahra AlHaj Issa, 4207551

ORAL AZACITIDINE MAINTENANCE IN FAVORABLE-RISK AML: ON BEHALF OF THE ISRAEL ACUTE LEUKEMIA GROUP (IALG)

EHA Library, Noa Hurvitz, 4207555

UNCOVERING THE CHARACTERISTICS OF ACCELERATED CLL THROUGH CLINICAL AND SINGLE‑CELL RNA-SEQ ANALYSIS

EHA Library, Francesco Angotzi, 4207561

3D CLL SPHEROID MODEL RECAPITULATES LYMPH NODE PHENOTYPES AND IN VIVO RESPONSES TO IBRUTINIB; A SINGLE-CELL CHARACTERIZATION

EHA Library, Eric Eldering, 4207563

MCL1 COPY NUMBER GAIN IS A RECURRENT MARK OF VENETOCLAX RESISTANCE IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Carolyne Croizier, 4207565

DISTINCT STEREOTYPED SUBSETS OF CHRONIC LYMPHOCYTIC LEUKEMIA REMODEL METABOLISM THROUGH A WARBURG-LIKE EFFECT

EHA Library, John Mollstedt, 4207567

ERIC TP53 VARIANT DATABASE IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): A COMMUNITY-DRIVEN RESOURCE FOR FUNCTIONAL AND CLINICAL INTERPRETATION

EHA Library, Jitka Malcikova, 4207568

INTRACLONAL DIVERSIFICATION IN IMMUNOGLOBULIN LIGHT CHAIN GENES REFINES PROGNOSTICATION IN EARLY-STAGE CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Jana Nabki, 4207569

DISSECTION OF BIALLELIC NOTCH1 DISRUPTION IN CHRONIC LYMPHOCYTIC LEUKEMIA REVEALS CHROMOSOME 9 COPY NEUTRAL-LOSS OF HETEROZYGOSITY

EHA Library, Giulia Ianna, 4207571